Sparfloxacin

Drug Profile

Sparfloxacin

Alternative Names: AT 4140; CI 978; PD 131501; RP 64206; Spara; Zagam

Latest Information Update: 30 Mar 2015

Price : $50

At a glance

  • Originator Dainippon Sumitomo Pharma
  • Developer AbbVie; Dainippon Sumitomo Pharma; Sam-A Corporation; Sumitomo Dainippon Pharma; Sun Pharmaceutical Industries; Teva Pharmaceutical Industries
  • Class Antibacterials; Fluoroquinolones
  • Mechanism of Action Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Bacterial infections; Pneumonia; Respiratory tract infections
  • Market Withdrawal Acute exacerbations of chronic bronchitis; Community-acquired pneumonia

Most Recent Events

  • 25 Mar 2015 Ranbaxy Laboratories has been acquired by Sun Pharmaceutical Industries
  • 19 Jun 2014 Dainippon Sumitomo Pharma is now called Sumitomo Dainippon Pharma
  • 20 Oct 2008 Ranbaxy Laboratories has been acquired by Daiichi Sankyo Company
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top